Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hemopoietic Stem Cell Transplantation in Thalassemia: A Report From the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010 Publisher Pubmed



Baronciani D1 ; Angelucci E1 ; Potschger U2 ; Gaziev J3 ; Yesilipek A4 ; Zecca M5 ; Orofino MG6 ; Giardini C7 ; Alahmari A8 ; Marktel S9 ; De La Fuente J10 ; Ghavamzadeh A11 ; Hussein AA12 ; Targhetta C1 Show All Authors
Authors
  1. Baronciani D1
  2. Angelucci E1
  3. Potschger U2
  4. Gaziev J3
  5. Yesilipek A4
  6. Zecca M5
  7. Orofino MG6
  8. Giardini C7
  9. Alahmari A8
  10. Marktel S9
  11. De La Fuente J10
  12. Ghavamzadeh A11
  13. Hussein AA12
  14. Targhetta C1
  15. Pilo F1
  16. Locatelli F13
  17. Dini G14
  18. Bader P15
  19. Peters C2
Show Affiliations
Authors Affiliations
  1. 1. Ematologia e Centro Trapianti, Ospedale Oncologico di Riferimento Regionale Armando Businco, Azienda Ospedaliera Brotzu, via Edward Jenner, Cagliari, 09121, Italy
  2. 2. St Anna Children's Hospital, Department of Pediatrics, Medical University, Vienna, Austria
  3. 3. International Center for Transplantation in Thalassemia and Sickle Cell Anemia, Rome, Italy
  4. 4. Pediatric Stem Cell Transplantation Unit, Akdeniz University School of Medicine, Antalya, Turkey
  5. 5. Department of Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
  6. 6. Department of Biomedical Science and Biotechnology, Second Paediatric Clinic, Bone Marrow Transplant Unit, University of Cagliari, Cagliari, Italy
  7. 7. Ematologia e Centro Trapianti, Ospedali Riuniti Marche Nord, Pesaro, Italy
  8. 8. King Faisal Specialist Hospital and Research Centre, Department of PHO and Stem Cell Transplantation, Riyadh, Saudi Arabia
  9. 9. Stem Cells Programme, IRCCS San Raffaele Scientific Institute, Milan, Italy
  10. 10. Division of Paediatrics, St Mary Hospital, London, United Kingdom
  11. 11. Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  12. 12. Pediatric Bone Marrow and Stem Cell Transplant, King Hussein Cancer Center, Al-Jubeiha Amman, Jordan
  13. 13. Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy
  14. 14. EBMT, Italy
  15. 15. Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, Frankfurta Main, Germany

Source: Bone Marrow Transplantation Published:2016


Abstract

Allogeneic hemopoietic stem cell transplantation (HSCT) is the only method currently available to cure transfusion-dependent thalassemia major that has been widely used worldwide. To verify transplantation distribution, demography, activity, policies and outcomes inside the European Group for Blood and Marrow Transplantation (EBMT), we performed a retrospective non-interventional study, extracting data from the EBMT hemoglobinopathy prospective registry database. We included 1493 consecutive patients with thalassemia major transplanted between 1 January 2000 and 31 December 2010. In total, 1359 (91%) transplants were performed on patients <18 years old, 1061 were from a human leukocyte Ag-identical sibling donor. After a median observation time of 2 years, the 2-year overall survival (OS) and event-free survival (EFS; that is, thalassemia-free survival) were 88±1% and 81±1%, respectively. Transplantation from a human leukocyte Ag-identical sibling offered the best results, with OS and EFS of 91±1% and 83±1%, respectively. No significant differences in survival were reported between countries. The threshold age for optimal transplant outcomes was around 14 years, with an OS of 90-96% and an EFS of 83-93% when transplants were performed before this age. Allogeneic HSCT for thalassemia is a curative approach that is employed internationally and produces excellent results. © 2016 Macmillan Publishers Limited.
Related Docs
1. The Effect of Bone Marrow-Derived Mesenchymal Stem Cell Co-Transplantation With Hematopoietic Stem Cells on Liver Fibrosis Alleviation and Survival in Patients With Class Iii Β-Thalassemia Major, Stem Cell Research and Therapy (2021)
2. Applied Stem Cell Research in Sickle Cell Disease, Comprehensive Hematology and Stem Cell Research: Volume 1-5 (2024)
3. Analysis of Determinant Factors of Liver Fibrosis Progression in Ex-Thalassemic Patients, International Journal of Hematology (2021)
4. Challenges in Managing Graft-Versus-Host Disease in Developing Countries: A Perspective, Bone Marrow Transplantation (2019)
Experts (# of related papers)
View all Related Experts
Amir Ali Hamidieh (2)
Azadeh Kiumarsi (2)